These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. Shen Q; Liu S; Chen Y; Yang L; Chen S; Wu X; Li B; Lu Y; Zhu K; Li Y J Hematol Oncol; 2013 Sep; 6():64. PubMed ID: 24004697 [TBL] [Abstract][Full Text] [Related]
23. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Belloc F; Airiau K; Jeanneteau M; Garcia M; Guérin E; Lippert E; Moreau-Gaudry F; Mahon FX Leukemia; 2009 Apr; 23(4):679-85. PubMed ID: 19158834 [TBL] [Abstract][Full Text] [Related]
24. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition. Simara P; Stejskal S; Koutna I; Potesil D; Tesarova L; Potesilova M; Zdrahal Z; Mayer J Am J Hematol; 2013 May; 88(5):385-93. PubMed ID: 23420553 [TBL] [Abstract][Full Text] [Related]
25. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884 [TBL] [Abstract][Full Text] [Related]
27. BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells. Chu S; Holtz M; Gupta M; Bhatia R Blood; 2004 Apr; 103(8):3167-74. PubMed ID: 15070699 [TBL] [Abstract][Full Text] [Related]
28. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells. Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333 [TBL] [Abstract][Full Text] [Related]
29. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803 [TBL] [Abstract][Full Text] [Related]
30. Targeted drugs in chronic myeloid leukemia. Gora-Tybor J; Robak T Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651 [TBL] [Abstract][Full Text] [Related]
31. Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Nicolini FE; Turkina A; Shen ZX; Gallagher N; Jootar S; Powell BL; De Souza C; Zheng M; Szczudlo T; le Coutre P Cancer; 2012 Jan; 118(1):118-26. PubMed ID: 21732337 [TBL] [Abstract][Full Text] [Related]